{"id":10187,"global_id":"arthramid.com\/au\/?id=10187","global_id_lineage":["arthramid.com\/au\/?id=10187"],"author":"9","status":"publish","date":"2025-09-18 11:49:09","date_utc":"2025-09-17 23:49:09","modified":"2025-11-06 13:44:51","modified_utc":"2025-11-06 00:44:51","url":"https:\/\/arthramid.com\/au\/event\/contura-at-london-vet-show\/","rest_url":"https:\/\/arthramid.com\/au\/wp-json\/tribe\/events\/v1\/events\/10187","title":"Contura Vet at London Vet Show","description":"
Discover Arthramid at London Vet Show 2025<\/strong><\/h5>\n

Join us at Europe’s premier veterinary event and discover how Arthramid\u00ae is transforming joint health across the globe.
\nThe London Vet Show<\/strong> presents an exclusive opportunity for European veterinarians to explore the science behind Arthramid’s innovative 2.5% injectable polyacrylamide hydrogel (iPAAG) technology. As the first and only treatment designed to target the synovium directly, Arthramid offers a new approach to managing osteoarthritis and joint lameness in both equine and canine patients.<\/p>\n

Hear from Dr. Jason Lowe<\/strong> – Arthramid’s Chief Veterinary Officer and Managing Director in two mini lectures at the event:<\/p>\n

Reframing 2.5%: iPAAG Insights Into the Mechanism and Medicine of Its Role in OA Therapy<\/strong>
\nThursday\u00a020 Nov 2025 | 14:00\u201315:00<\/p>\n

Rethinking OA Therapy: 2.5% iPAAG as a Novel OA Modulator
\n<\/strong>with Matt Brunke (VetDVM, DACVSMR, Fellow IAVRPT)
\nFriday 21 Nov 2025 | 10:45\u201311:45<\/p>\n

 <\/p>\n

Dr. Lowe will be at the Nupsala stand (H10) throughout the event and is available to discuss:<\/p>\n